Stay informed
MAPS practices the principle of Open Science, Open Books, transparently sharing what we learn. Through our publications, we seek to Be the Bridge, building common knowledge between the medical, the mystical, the marginalized, and the mainstream.
Are you a member of the media? Visit our newsroom.
MAPS Remains Hopeful, Awaits FDA Decision on MDMA-Assisted Therapy for PTSD
June 17, 2024
Dear Friends and Allies, On June 4, 2024, the U.S. Food and Drug Administration (FDA) convened a meeting of the Psychopharmacologic Drugs Advisory Committee to evaluate Lykos Therapeutics’ (Lykos) New …
LEGISLATIVE WRAP UP – Summer 2024
June 6, 2024
The first half of 2024 has been riveting for a few reasons. By now, Oregon’s regulated access program has been in effect for eighteen months, with thousands of people having received psilocybin services; …
Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSD
April 24, 2024
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
March 11, 2024
FOR IMMEDIATE RELEASE: March 11, 2024 [San Jose, California 03/11/24] – The Multidisciplinary Association for Psychedelic Studies (MAPS) has partnered with the City and County of Denver to provide comprehensive …
MAPS Announces Celestial Plans for Its 38th Anniversary
March 7, 2024
FOR IMMEDIATE RELEASE: March 07, 2024 [San Jose, California 03/07/24] – MAPS (Multidisciplinary Association for Psychedelic Studies) is excited to announce its collaboration with Texas Eclipse 2024 for …
Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado
February 13, 2024
FOR IMMEDIATE RELEASE: February 13, 2024 [San Jose, California 02/13/24] – The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference …
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
February 9, 2024
FOR IMMEDIATE RELEASE: February 9, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) congratulates Lykos Therapeutics, formerly MAPS Public Benefit Corporation, on its announcement …
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
January 16, 2024
FOR IMMEDIATE RELEASE: January 16, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) reintroduces itsFiscal Sponsorship Program, signaling a new era of support for grassroots organizations …
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
January 5, 2024
FOR IMMEDIATE RELEASE: January 5, 2024 A decade after it was founded as a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation (MAPS …
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
December 13, 2023
FOR IMMEDIATE RELEASE: December 13, 2023 MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from …
49ers’ Jon Feliciano supports MAPS as part of the 2023 NFL “My Cleats, My Cause” campaign
December 4, 2023
FOR IMMEDIATE RELEASE: December 4, 2023 Yesterday’s highly anticipated football game between the San Francisco 49ers and the Philadelphia Eagles brought additional excitement to the field thanks to 49ers’ …
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
November 11, 2023
FOR IMMEDIATE RELEASE: November 11, 2023 In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical …